Viking Therapeutics Inc logo

VKTX

Viking Therapeutics Inc

$3.67

Earnings Summary

Revenue
$0Mn
Net Profits
$-17.43Mn
Net Profit Margins
-Inf%

Highlights

Revenue:

Viking Therapeutics Inc’s revenue fell -100% since last year same period to $0Mn in the Q2 2022. On a quarterly growth basis, Viking Therapeutics Inc has generated NaN% jump in its revenue since last 3-months.

Net Profits:

Viking Therapeutics Inc’s net profit fell -13.33% since last year same period to $-17.43Mn in the Q2 2022. On a quarterly growth basis, Viking Therapeutics Inc has generated -8.25% fall in its net profits since last 3-months.

Net Profit Margins:

Viking Therapeutics Inc’s net profit margin fell -Inf% since last year same period to -Inf% in the Q2 2022. On a quarterly growth basis, Viking Therapeutics Inc has generated NaN% jump in its net profit margins since last 3-months.

Earnings per share (EPS) Estimates

Earnings per share (EPS) estimates of the Viking Therapeutics Inc post its latest quarter earnings

EPS Estimate Current Quarter
-0.23
EPS Estimate Current Year
-0.23

Highlights

EPS Estimate Current Quarter:

Viking Therapeutics Inc’s earning per share (EPS) estimates for the current quarter stand at -0.23 - a -9.52% fall from last quarter’s estimates.

EPS Estimate Current Year:

Viking Therapeutics Inc’s earning per share (EPS) estimates for the current year stand at -0.23.

Key Ratios

Key ratios of the Viking Therapeutics Inc post its Q2 2022 earnings

Earning Per Share (EPS)
-0.23
Return on Assets (ROA)
-0.15
Return on Equity (ROE)
-0.25
Dividend Per Share (DPS)
0

Highlights

Earning Per Share (EPS):

Viking Therapeutics Inc’s earning per share (EPS) fell -15% since last year same period to -0.23 in the Q2 2022. This indicates that the Viking Therapeutics Inc has generated -15% annual rate of fall in its earning per share (EPS) in the last 4 quarters.

Return on Assets (ROA):

Return on assets (ROA) indicates the profitability of the company in relation to its total assets. This ratio tells the financial health of the company. The higher the ROA, the better the company’s financial health. If any company has a ROA in the range of 5% to 20% - it is generally considered good. ROA above 20% is generally considered excellent. Viking Therapeutics Inc’s return on assets (ROA) stands at -0.15.

Earning Per Share (EPS):

The Return On Equity ratio indicates a company’s ability to turn equity capital received from shareholders into profits. ROE highlights the efficiency of equity capital in running the business. Generally, a return on equity in double digits is considered good. Viking Therapeutics Inc’s return on equity (ROE) stands at -0.25.

Dividend Per Share (DPS):

Viking Therapeutics Inc declared 0 dividend per share during the earnings announcement for Q2 2022.

Earnings Calendar

Earnings DateEstimated EPSReported EPSSurprise %
2022-04-27
-0.19
-0.21
-10.53%
2022-07-27
-0.21
-0.23
-9.52%

Company Information

Viking Therapeutics is a clinical-stage biopharmaceutical company focused on the development of novel, orally available, first-in-class or best-in-class therapies for the treatment of metabolic and endocrine disorders. Viking's research and development activities leverage its expertise in metabolism to develop innovative therapeutics designed to improve patients' lives. The company's clinical programs include VK2809, a novel, orally available, small molecule selective thyroid hormone receptor beta agonist for the treatment of lipid and metabolic disorders, which is currently being evaluated in a Phase 2b study for the treatment of biopsy-confirmed non-alcoholic steatohepatitis (NASH) and fibrosis. In a Phase 2 trial for the treatment of non-alcoholic fatty liver disease (NAFLD) and elevated LDL-C, patients who received VK2809 demonstrated statistically significant reductions in LDL-C and liver fat content compared with patients who received placebo. The company is also developing VK0214, a novel, orally available, small molecule selective thyroid hormone receptor beta agonist for the potential treatment of X-linked adrenoleukodystrophy (X-ALD). VK0214 is currently being evaluated in a Phase 1 first-in-human clinical trial. The company holds exclusive worldwide rights to a portfolio of five therapeutic programs, including those noted above, which are based on small molecules licensed from Ligand Pharmaceuticals Incorporated.

Organisation
Viking Therapeutics Inc
Headquarters
San Diego, California, United States
Employees
19
Industry
Health Technology
CEO
Brian Lian